Newpath Partners
Boston, Massachusettsnewpath.partners
Overview
Newpath Partners is a venture capital firm dedicated to excellent science and to forming partnerships based on trust and a shared vision . The firm focuses on venture capital investments in disruptive treatments and technologies in the life sciences space . Newpath collaborates with academics and founders to translate scientific discoveries into biotechnology companies across the US .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Myeloid Therapeutics | May 2026 | Series B | Lead |
| CREATE Medicines | May 2026 | Series B | Lead |
| Leal Therapeutics | Aug 2025 | Series A | Co-investor |
| nChroma Bio | Dec 2024 | Series I | Lead |
| Metsera | Nov 2024 | Series B | - |
Key People
Daniel Yadegar
Co-Founder and Chief Medical Officer
Thomas Cahill
Co-Founder
Tom M. Thomas
Investor
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
